I'm patient, and accumulating as well. Cant wait for the next news like operations update or an analyst review, at a market cap of 75M$, this will move up several fold easy!

 

captsecord wrote:

 

market cap 75M$, plenty of cash for nearly 2 years.  ALL going as best it can go. Pipeline is good, money is good, sp is extremely cheap... i'm glad im loaded!!!!

 

Key Corporate and R&D Priorities
 

  • Upon closing of sale of the Rare Pediatric Disease Priority Review Voucher ("PRV") for US$105 million, Liminal will be entitled to receive an amount equal to 70% of the net proceeds, which would be payable to Liminal by its subsidiary Prometic Biotherapeutics Inc. ("PBT") prior to closing the divestment of its remaining plasma-derived therapeutics business operated through PBT to Kedrion S.p.A. ("Kedrion").
  • Pending full analysis of the complete PK data set from the phase 1 multi-ascending dose ("MAD") clinical trial, we intend to determine the choice of other potential indication(s) for further development of fezagepras. No dose-limiting adverse events or other potential safety signals have been observed in the phase 1 MAD clinical trial to date.
  • Pending the outcome of our pre-clinical research, and successful nomination of a pre-clinical drug candidate, we plan to initiate a pre-clinical Investigational New Drug ("IND") enabling program to support a first-in-human Phase 1 single-ascending dose clinical trial of our GPR84 antagonist drug candidate to be selected in healthy volunteers for safety and tolerability.
  • Pending the outcome of our pre-clinical research, and successful nomination of a pre-clinical drug candidate, we plan to initiate a pre-clinical IND enabling program to support a first-in-human Phase 1 single-ascending dose clinical trial of our OXER1 drug candidate to be selected in healthy volunteers for safety and tolerability.